Using our screening platform, which measures various aspects of ERα signaling and cell proliferation simultaneously, we have shown that drugs capable of inducing the degradation of ERα, rather than directly binding to it, can effectively prevent BC cell proliferation. The gene discussed is ESR1; the disease is breast cancer.